Directorio

A registry is a database of information (data) about patients living with a specific condition. Scientists study the information in the registry to increase what we know about the condition so we can develop better treatments in the future. This registry will help us better understand lupus and how it is managed, including how different treatments work and their long-term safety.

We are doing this study to look at components of the blood to see if there are features that distinguish people with dystonia from people without dystonia. Identifying "biomarkers" in the blood that are associated with dystonia is greatly needed to help more accurately diagnosis dystonia and to identify subsets of dystonias that may have shared mechanisms. Being able to group individuals by underlying mechanisms can guide people with dystonia to the most appropriate future treatments that act specifically to correct one cause or another.

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

We are doing this study to compare the results of typical chemotherapy on its own to high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. We want to know which option has the best outcomes for people with periperhal T-cell lymphoma.

We are doing this study to compare the safety and effects of stopping the standard melanoma treatments of nivolumab + pembrolizumab or nivolumab + relatlimab at different times. We hope this study will help us discover certain markers from imaging and biopsies that can signal when it is the appropriate time to stop therapy.

We are doing this study to compare the usual treatments of surgery alone to using chemotherapy before surgery. We want to know if adding doxorubicin and ifosfamide chemotherapy for liposarcoma (LPS) or doxorubicin and dacarbazine chemotherapy for leiomyosarcoma (LMS) before surgery can improve the long-term survival for patients with these cancers.

We are doing this study to find out if an experimental combination of drugs is an effective treatment for ALL. The combination used in the study is blinatumomab (the study drug) + steroids and tyrosine kinase inhibitors (TKI). We want to know if this drug combination is more effective than the standard treatment of chemotherapy + steroids and TKI.

We are doing this study to find out how different imaging techniques can help with the evaluation of glioblastoma.